Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells
Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells
复制标题
DOI：
10.1016/j.jbiotec.2010.06.023
复制
发表时间：
2010-10-01
影响因子：
4.1
通讯作者：
Mandenius, Carl-Fredrik
中科院分区：
文献类型：
--
作者：
Andersson, Henrik;Steel, Daniella;Mandenius, Carl-Fredrik
人类胚胎干细胞（hESC）衍生的心肌细胞在目前的研究中被用于在生物传感器设置中测试药物诱导的心脏毒性。体外测试替代方案的设计提供了一个新的机会，超越以前基于啮齿动物细胞或细胞系的方法，因为它具有显着更高的毒理学相关性。在本报告中，我们展示了当心脏细胞暴露于众所周知的心脏活性药物化合物时，hesc来源的心肌细胞如何释放可检测水平的两种临床决定性心脏生物标志物，心脏肌钙蛋白T和脂肪酸结合蛋白3。阿霉素。释放由免疫生物传感器技术表面等离子体共振监测，由于其在复杂介质中并行和高通量分析的能力，特别适合。(C) 2010 Elsevier B.V.版权所有
Human embryonic stem cell (hESC) derived cardiomyocytes are in the present study being used for testing drug-induced cardiotoxicity in a biosensor set-up. The design of an in vitro testing alternative provides a novel opportunity to surpass previous methods based on rodent cells or cell lines due to its significantly higher toxicological relevance. In this report we demonstrate how hESC-derived cardiomyocytes release detectable levels of two clinically decisive cardiac biomarkers, cardiac troponin T and fatty acid binding protein 3, when the cardiac cells are exposed to the well-known cardioactive drug compound. doxorubicin. The release is monitored by the immuno-biosensor technique surface plasmon resonance, particularly appropriate due to its capacity for parallel and high-throughput analysis in complex media. (C) 2010 Elsevier B.V. All rights reserved.